Clinical Trials
24 trialsFruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
BEST
Shanghai Zhongshan Hospital
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
ImmVirx Pty Ltd
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
The First People's Hospital of Changzhou
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Shanghai Changzheng Hospital
Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
Zhejiang Cancer Hospital
IMPROVE
Fudan University
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Sun Yat-sen University
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
Sun Yat-sen University
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
Huazhong University of Science and Technology
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
Fudan University
Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients
ChineseAMS